Mitozolomide

From Wikipedia, the free encyclopedia

ATC code
  • none
Mitozolomide
Clinical data
ATC code
  • none
Identifiers
  • 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.079.921 Edit this at Wikidata
Chemical and physical data
FormulaC7H7ClN6O2
Molar mass242.62 g·mol−1
3D model (JSmol)
  • NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12
  • InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15) ☒N
  • Key:QXYYYPFGTSJXNS-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

Related Articles

Wikiwand AI